Warning: DOMDocument::load(http://www.iovs.org/rss/current.xml) [domdocument.load]: failed to open stream: HTTP request failed! HTTP/1.1 404 Not Found in /pub/home/eyenews/eyenews_ru/site/plugins/news/classess/news.inc.php on line 322

Warning: DOMDocument::load() [domdocument.load]: I/O warning : failed to load external entity "http://www.iovs.org/rss/current.xml" in /pub/home/eyenews/eyenews_ru/site/plugins/news/classess/news.inc.php on line 322

Warning: Cannot modify header information - headers already sent by (output started at /pub/home/eyenews/eyenews_ru/site/plugins/news/classess/news.inc.php:322) in /pub/home/eyenews/eyenews_ru/site/Site.inc.php on line 271

Warning: Cannot modify header information - headers already sent by (output started at /pub/home/eyenews/eyenews_ru/site/plugins/news/classess/news.inc.php:322) in /pub/home/eyenews/eyenews_ru/site/Site.inc.php on line 273
eyeNEWS — Все новости офтальмологии. Версия 6.0
Конгресс 2014
Основные мероприятия ассоциации офтальмологов
Первая пятница декабря
Новости офтальмологии
Оргкомитет: тел.: (347) 273-49-97; факс: (347) 272-08-52 Сайт конференции «Восток-Запад» www.eastwestufa.ru Сайт Уфимского НИИ глазных болезней: www.ufaeyeinstitute.ru E-mail:east-west-ufa@yandex.ru, ufaeyenauka@mail.ru
ournal of Glaucoma is currently the only scientific journal devoted to glaucoma that is both indexed and has an impact factor, giving the Journal a unique position in the glaucoma community. In conjunction with the World Glaucoma Association, the publisher will be offering remarkably low rates for both hard copy and electronic subscriptions. More information about this will follow from the publisher and the WGA once details of the new relationship are finalised.
Уважаемый коллега! Очередной выпуск журнала «Офтальмология» приурочен к международной конференции «Актуальные проблемы офтальмологии», посвященной 95-летнему юбилею академика Зарифы Алиевой. Просим присылать статьи на электронный адрес oftal.jurnal@mail.ru до 15.02.2018г. Требования оформления статей размещены на сайте www.oftalmologiya.az С уважением, Редакция журнала «Офтальмология»
Twenty-five years old is a good age to be. Any older and your hearing starts to decline; the loss may be barely detectable at that stage – but it’s only going in one direction. By the start of your fourth decade, your bone and skeletal muscle mass starts to decline, and by your mid-forties, a number of ocular diseases start to manifest: incipient cataract, slight drusen deposits, a small raise in IOP... and presbyopia. Some people experience it in their forties, others in their fifties. It’s most definitely age-related, and for now, almost certainly inescapable
At a Glance For the first time, aqueous angiography has been applied to living subjects (both humans and non-human primates) Real-time data from live patients was consistent with previous post-mortem aqueous angiography: outflow is segmentally heterogeneous Furthermore, live-patient data confirmed a pulsatility to outflow and resulted in the discovery of dynamic features of aqueous outflow – a unique observation Increasingly, aqueous angiography appears to have the potential to guide surgery to patient-specific regions, thereby enhancing MIGS outcomes.
Первая пятница декабря. Теории, тенденции, технологии. Почти 1400 участников (докторов, сотрудников оргкомитета, представителей партнеров, технических служб). Встреча Экспертных советов по глаукоме РФ, СНГ, Грузии и Балтии. Клуб глаукоматологов Восточной Европы, клуб заведующих глаукомных отделов/отделений РФ и СНГ, участие представителей Европейского глаукомного общества. 23 страны (от США до Сингапура), 131 город! Крупнейший глаукомный форум в Восточной Европе в этом году
Симпозиум “Проблемные вопросы глаукомы” является ежегодным мероприятием, предназначенным расширить и углубить знания российских офтальмологов в вопросах диагностики и лечения глаукомы, а также открыть диалог между российскими и зарубежными докторами по наиболее сложным и нерешенным аспектам, касающимся этого заболевания. В этом году будет проведен телемост "Москва - Нью-Йорк - Лондон - Регионы РФ" при участии Р.Рича (Нью-Йорк, США), К.Бергойна (Портланд, США), К.Тама (Гонконг, Китай), К.Мартина (Кембридж, Великобритания), С.Мильёр (Милан, Италия) и К. Лёна (Гонконг, Китай). Уже сейчас на сайте опубликована лекция проф. Р. Рича (Нью-Йорк, США) ПСВЕДОЭКСФОЛИАТИВНЫЙ СИНДРОМ (ПЭС): НОВЫЕ ГОРИЗОНТЫ
An FDA advisory committee voted unanimously that Spark Therapeutics’ Luxturna gene therapy for retinal dystrophy has an overall favorable benefit-risk profile. Sixteen members of the Cellular, Tissue, and Gene Therapies Advisory Committee voted yes and zero voted no, with zero abstentions, on the following question: Considering the efficacy and safety information provided in the briefing document, as well as the presentations and discussions during the AC meeting, does voretigene neparvovec have an overall favorable benefit-risk profile for the treatment of patients with vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy?
В середине марта будет представлен широкой публике! Ждем,с!
Abstract: Vernal keratoconjunctivitis (VKC) is a chronic allergic conjunctivitis that is most often seen in young, males. Although most types of allergic conjunctivitis do not affect vision, VKC is unusual in that damage to the cornea from the condition can result in vision loss. Although it is typically seasonal, year-round symptoms can be seen, which can lead to uncertain diagnoses being made. Although the pathophysiology of VKC is better understood in recent years, allowing more targeted therapies, management of these patients can still be very challenging, and complications can occur. As such, aggressive management of VKC is necessary, especially since vision loss in the amblyogenic age range can be permanent
Ted Garway-Heath, as in-coming president, has big shoes to fill! The EGS goes from strength to strength in achieving its vision to promote the best possible well being and minimal glaucoma-induced visual disability in individuals with glaucoma within an affordable healthcare system. This would not be possible without the teamwork and friendship of many contributors
The International Council of Ophthalmology (ICO) Fellowships Program was organized to help promising young ophthalmologists from developing countries improve their practical skills and broaden their perspectives of ophthalmology. Fellows are expected to bring the acquired knowledge and skills back to their home countries and take part in programs to preserve vision and prevent blindness. For the ICO-Allergan Research Fellowship we encourage applicants from all countries. The ICO gratefully recognizes grants, gifts, and pledges to the ICO Fellowships Program. Support ICO Fellowships by contributing to the ICO, ICOFoundation, or the International Ophthalmological Fellowship Foundation (IOFF). The IOFF was formed in Germany to support the fellowships. View ICO Fellowship donors.
Abstract submission deadline for the 2nd International Swept Source OCT & Angiography conference has been extended to December 31st. Submit your abstract to www.issoct.com. Competition The best submission (talk or poster) will be selected by the ISSOCT Scientific Committee. The winner will receive an invitation to speak at the 3rd ISSOCT in 2019 which includes a travel grant and other benefits. Visit www.issoct.com for rules and additional information including travel grants.
Fellowship Award The New World Medical Fellowship Award supports future health care leaders who are dedicated to making global humanitarian work an integral part of their careers in glaucoma. The Fellowship Award is comprised of $10,000 in travel support for a minimum of one ophthalmic mission in a developing nation within a single academic year. Any remaining funds can be used to attend national or international ophthalmic conferences and/or obtain training that will enhance future efforts to deliver care to underserved populations. The selection committee will choose the applicant who best embodies the spirit of these objectives as the annual New World Medical Fellow.
The World Glaucoma Association aspires to be the most important source of education for ophthalmologists and other healthcare providers related to glaucoma. Our bi-annual World Glaucoma Congress (WGC) is the cornerstone of our knowledge platform. We also provide the Educational Portal with recorded sessions from past WGC's, develop and publish International Glaucoma Review (IGR) and organize a Fellowship Program to match international ophthalmologists with top academic programs and provide financial support for attendance at the WGC.
Мы действительно будем рады всех видеть) Подробнее на сайте Новости глаукомы Российского глаукомного общества
Glaucoma is the leading cause of irreversible blindness worldwide, with an estimated 70 million people affected by the condition. With the aging population, it is expected that the prevalence of glaucoma will continue to increase, resulting in an estimated 80 million people with glaucoma by 2020. Recent advances in imaging have facilitated earlier glaucoma diagnosis and subsequent timely initiation of therapy, potentially reducing irreversible blindness and loss of quality of life. Therapies for glaucoma either increase outflow or decrease production of aqueous humor to reduce intraocular pressure (IOP), but IOP must be tightly controlled to provide optimal patient outcomes. In this activity, leading clinicians will evaluate clinical evidence for the safety and efficacy of established, new, and emerging classes of glaucoma medications, as well as discuss their mechanisms of action for the effective management of IOP.
Dr. Paul Singh highlighted the diagnostic aspect of SLT during the 2017 Combined Ophthalmic Symposium in Austin, Texas. When asked if there was still a role for trabeculoplasty in managing glaucoma, Dr. Singh emphasized the many options now available for treating glaucoma patients in a customized fashion. He went on to note that in his practice, he has asked himself if SLT may provide some knowledge as to where the resistance in out ow may be: “when SLT works, could it be that the trabecular meshwork is the main area of resistance... or when it doesn’t work does this tell us that maybe it is in the Schlemm’s canal or distal to it.” In his opinion, SLT may help give a better understanding preoperatively of where the resistance lies.
Key Points Question What is the association of systemic medication with intraocular pressure in a multiethnic Asian population? Findings In a post hoc analysis of a population-based study of 8063 participants from 3 ethnic groups (Chinese, Malays, and Indians), lower intraocular pressure was more likely associated with participants using systemic β-blockers, whereas higher intraocular pressure was more likely associated with participants using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins, or sulfonylureas. Meaning The effect of commonly dispensed systemic medication on intraocular pressure may have implications for glaucoma risk in individuals taking these medications for coexisting comorbidities.

Warning: Cannot modify header information - headers already sent by (output started at /pub/home/eyenews/eyenews_ru/site/plugins/news/classess/news.inc.php:322) in /pub/home/eyenews/eyenews_ru/cms/includes/utils/Cookie.inc.php on line 60
Что "заставляет" Вас заниматься научными исследованиями?
Популярная пресса
Интересное видео
Клуб молодых офтальмологов

МОО "Глаукомное общество"

Экспертный совет по глаукоме

Диабет. Рекомендации

Глаукома. Рекомендации ICO

Новостная лента на Twitter
Новости зарубежной офтальмологии